uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted May 13, 2015

Amberen Weight Loss Claims Not Supported by Evidence, Says FTC

On May 12, 2015, the FTC announced it filed a complaint to stop Lunada Biomedical Inc. from advertising that its product Amberen is clinically proven to cause substantial weight loss in women over 40.

According to the FCC, advertisements for Amberen claim it can cause significant weight loss and loss of belly fat, restore hormonal balance, and is the "the ONLY product on the market today clinically proven to cause sustained weight loss for women over 40," -- despite the fact that studies do not support these claims. In one clinical trial, a double dose of Amberen was used and weight loss was not specifically measured, while a second clinical trial failed to show a statistically significant difference between the test and control groups.

In addition, the FTC stated the promise that consumers could try Amberen risk free for 30 days was inaccurate since customers were required to return two unopened boxes at their own expense in order to qualify for a refund.

See's Review of Weight Loss Supplements for tests of related products.

See Related Warnings:

Marketers Charged with Using Stolen Email Accounts to Promote Weight Loss Supplements Temporarily Shut Down

FTC Mails Refund Checks for Calcium Supplements

FTC Files Against Maker of Calcium and Fertility Supplements

Restitution Program for Purchases of Lane Labs' Products

FTC Mails Refund Checks to Consumers Who Purchased Weight Loss Pills

FTC Says Company Made "Outrageous" Weight Loss Claims

FTC Mails Refund Checks to Consumers Who Purchased Sensa

Four Companies Settle FTC Charges of Deceptive Weight Loss Claims

Sensa Settles Second False Advertising Lawsuit

To read the FTC's press release, use the link below.